The global biosafety testing market is expected to grow 12% from $3.21 billion in 2019 to $7.25 billion in 2027. It serves as an essential contributing factor to improved drug development and subsequent commercialization, which is expected to drive market growth. This is to increase the need to study and ensure the safety of targeted and specific therapies, circumvent possible shortcomings, and evaluate their outcomes.
A full report of Biological Safety Testing Market available at https://www.orionmarketreports.com/biological-safety-testing-market/11466/
Biological Safety Testing Market: Segmentation
By Product & Services
• Consumables
• Instrument
• Services
By Application
• Vaccine Manufacturing
• Monoclonal Antibodies Manufacturing
• Cellular & Gene Therapy Products Manufacturing
• Blood and Blood Products Manufacturing
• Other Application
By Test Type
• Endotoxin Test
• Sterility Test
• Mycoplasma Tests
• Bioburden Tests
• Residual Host-Cell Proteins & DNA Detection Tests
• Virus Safety Test
Major Players
• Eurofins Scientific
• Lonza
• Merck KGaA
• Promega Corporation
• Thermo Fisher Scientific
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
